You should separate out trial design and the endpo

You should separate out trial design and the endpoints leveraged to prove efficacy and gain a better understanding of what is going on from real-world treatment and monitoring of disease state. Physicians are most likely going to choose labs that are traditional markers for liver inflammation like AST and ALT that are part of a routine metabolic panel. Potassium levels are way off target…potassium needs to be in a tight range or your kidneys are going to react to adjust…it is also more heavily influenced by other factors such as kidney disease, dehydration and even potassium supplementation. If the patient has hypokalemia the physician is more likely to question whether the cause might be from vomiting and diarrhea…the first impulse is not the liver.